genomic medicine News
-
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10th at 7:00 a.m. Eastern Time. The virtual session may be accessed on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The ...
-
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date: Thursday, June 9 at 9:00 a.m. Eastern Time Guggenheim I&I Spotlight Series – Treg-based Therapies Date: Tuesday, July 12 at 2:45 p.m. Eastern Time Access links for presentations, ...
-
SeqOne wins prestigious iLab grant to improve genomics analysis software in healthcare
SeqOne a French start-up in the genomic medicine market is proud to announce that it has been awarded an i-Lab grant by the Ministry of Education and Technology. i-Lab is a national competition open to all French start-ups designed to identify the most promising technical innovations by France’s most forward-thinking start-ups. The award is associated with a grant aimed at helping each ...
-
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to be dosed in third quarter of 2022 Preliminary proof-of-concept data presented at ASH 2021 showed ...
-
Advances in Newborn SMA Screening research by SNP Biotechnology
BSD Robotics is proud to share a recent study conducted by SNP Biotechnology R&D Ltd “A new line method; A direct test in spinal muscular atrophy screening for DBS” now published in the journal of Molecular Genetics and Genomic Medicine. Given spinal muscular atrophy (SMA) is one of the most prevalent genetic disorders affecting young children and a major cause of death in ...
By BSD Robotics
-
Michael Blum joins SeqOne Genomics to head the company’s Research and Development
SeqOne Genomics, today announced that Michael Blum, Ph.D. is joining the company to lead its research and development department. He is tasked with driving SeqOne’s R&D strategy notably in the area of rare diseases and oncology through the use of machine learning and data science. Michael started his career as a biostatistician and bioinformatician at the CNRS where he developed ...
-
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
-
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progression of Sangamo’s pre-clinical ...
-
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
No adverse events related to investigational SAR445136 were reported All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 ...
-
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in ...
-
An Australian first for lupin genome project
Being conducted in collaboration with the Centre for Food and Genomic Medicine (CFGM) in Perth, WA, the three-year, $1.5 million project will enable researchers and breeders to accelerate lupin crop improvements such as drought tolerance, disease resistance and optimal flowering time. The research team will build upon established resources and employ powerful next-generation sequencing ...
-
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated All four patients in the first two dose cohorts exhibited above normal α-Gal A activity, which was maintained for up to one year for the first patient treated Based on these data, Sangamo has initiated Phase 3 planning The fifth patient was recently dosed, in the third dose cohort Q3 ...
-
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
-
Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100® (Blood Volume Analyzer) with the United States Department of Veterans Affairs
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume Analysis guided management of acute decompensated heart failure (ADHF) utilizing the BVA-100 blood test. Over 6 million Americans suffer from heart failure, one of the most ...
-
Intus Bio Launches NanoID High-Resolution Microbiome Kits and Software using Patented Long Amplicon Technology for Oxford Nanopore Systems
Intus Biosciences, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, recently unveiled a powerful new analysis solution for Oxford Nanopore Systems. Shoreline Complete NanoID is the fastest and most complete microbiome sample prep kit for long-read NGS analysis for Oxford Nanopore Systems. Leave no microbe behind from any ...
-
Eurofins Biomnis and Seqone Partner to Improve Clinical Access to Whole Exome Testing
Eighty percent of rare diseases are genetic in origin and result from a small number of genetic mutations. Identifying these variations is essential in diagnosing the diseases and can dramatically improve patient care. Making Whole Exome sequencing more affordable to improve diagnostic efficiency Since 2017, Eurofins Biomnis has offered “Whole Exome” sequencing which, starting from ...
-
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The Alta study data, in patients with severe hemophilia A, are being presented today at the 63rd American ...
-
Seven Bridges Launches the GRAFTM Population Solution
Seven Bridges, the industry-leading bioinformatics ecosystem provider, today announced the launch of the GRAFTM Population Solution, a set of workflows, services and population-specific graph references to enable large-scale human population studies through more accurate read alignment and variant discovery. Included in today’s release are an updated population-specific NGS analysis ...
-
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing RNA components to the liver Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the ...
By Bayer AG
-
BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson’s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you